Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Capital Expenditures (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 2 years of Capital Expenditures data on record, last reported at $20000.0 in Q3 2022.

  • For Q3 2022, Capital Expenditures changed N/A year-over-year to $20000.0; the TTM value through Dec 2022 reached $1.9 million, changed N/A, while the annual FY2022 figure was $1.9 million, 48475.0% up from the prior year.
  • Capital Expenditures reached $20000.0 in Q3 2022 per AVIR's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.2 million in Q2 2022 and bottomed at $5000.0 in Q4 2020.